Tansu Kucuk1, Hakan Kozinoglu, Ayten Kaba. 1. Department Obstetrics and Gynaecology, GATA School of Medicine, 06018 Etlik, Ankara, Turkey. tansukucuk@gmail.com
Abstract
OBJECTIVE: The efficacy of growth hormone co-stimulation to long luteal GnRHa regimen in poor responders to COH for IVF was assessed. METHODS: This prospective, randomized, clinical trial was performed in a private assisted reproduction center. The study involved 61 patients who responded poorly to high dose gonadotropin treatment in their first cycles in the same center. Study group of 31 patients were givengrowth hormone co-treatment, daily subcutaneous injection of 4 mg from day 21 of preceding cycle along with GnRHa, until the day of hCG. Control group of 30 patients received the same treatment protocol except the growth hormone cotreatment. Primary end-point of the study was the number of oocytes fertilized whereas the pregnancy rate was the secondary end-point. RESULTS: Patients' demographic characteristics did not differ significantly between the two groups. 2PNs in growth hormone co-treatment group was significantly higher than the control group (4.4 +/- 1.8 vs 1.5 +/- 0.9, p < 0.001). Although more pregnancies and more clinical pregnancies with fetal heart beat were achieved in growth hormone group (12/31), compared to the control group (6/30), the difference did not reach to statistical significance. CONCLUSION:Poor responder women undergoingrepeated assisted reproduction treatment and co-stimulated with GH achieve more oocytes, higher fertilization rate if growth hormone started in the luteal phase of previous cycle, as compared with women of the same status treated with GnRHa long protocol. The study was unable to show that clinical pregnancy rate was increased significantly.
RCT Entities:
OBJECTIVE: The efficacy of growth hormone co-stimulation to long luteal GnRHa regimen in poor responders to COH for IVF was assessed. METHODS: This prospective, randomized, clinical trial was performed in a private assisted reproduction center. The study involved 61 patients who responded poorly to high dose gonadotropin treatment in their first cycles in the same center. Study group of 31 patients were given growth hormone co-treatment, daily subcutaneous injection of 4 mg from day 21 of preceding cycle along with GnRHa, until the day of hCG. Control group of 30 patients received the same treatment protocol except the growth hormone cotreatment. Primary end-point of the study was the number of oocytes fertilized whereas the pregnancy rate was the secondary end-point. RESULTS:Patients' demographic characteristics did not differ significantly between the two groups. 2PNs in growth hormone co-treatment group was significantly higher than the control group (4.4 +/- 1.8 vs 1.5 +/- 0.9, p < 0.001). Although more pregnancies and more clinical pregnancies with fetal heart beat were achieved in growth hormone group (12/31), compared to the control group (6/30), the difference did not reach to statistical significance. CONCLUSION: Poor responder women undergoing repeated assisted reproduction treatment and co-stimulated with GH achieve more oocytes, higher fertilization rate if growth hormone started in the luteal phase of previous cycle, as compared with women of the same status treated with GnRHa long protocol. The study was unable to show that clinical pregnancy rate was increased significantly.
Authors: Anne Bachelot; Philippe Monget; Prune Imbert-Bolloré; Karen Coshigano; John J Kopchick; Paul A Kelly; Nadine Binart Journal: Endocrinology Date: 2002-10 Impact factor: 4.736
Authors: A Barreca; P G Artini; P Del Monte; P Ponzani; P Pasquini; G Cariola; A Volpe; A R Genazzani; G Giordano; F Minuto Journal: J Clin Endocrinol Metab Date: 1993-07 Impact factor: 5.958
Authors: Carlo Alviggi; Peter Humaidan; Colin M Howles; Donald Tredway; Stephen G Hillier Journal: Reprod Biol Endocrinol Date: 2009-09-22 Impact factor: 5.211